BioCentury | Jan 17, 2019
Emerging Company Profile
Zelluna’s solid TCR plans
...portfolio of TCRs against antigens that are critical to tumor survival: TERT, KRAS and TGFBR2. Oslo University Hospital...
...direct cytolytic approach preferable. Zelluna has in-licensed the TCRs that ZI-H04 and ZI-T01 express from Oslo University Hospital...
...focus: Cancer Clinical status: Preclinical Founded: 2016 by Radforsk, Birk Venture and Inven2 University collaborators: Oslo University Hospital...
...direct cytolytic approach preferable. Zelluna has in-licensed the TCRs that ZI-H04 and ZI-T01 express from Oslo University Hospital...
...focus: Cancer Clinical status: Preclinical Founded: 2016 by Radforsk, Birk Venture and Inven2 University collaborators: Oslo University Hospital...